July 8, 2025
| Today’s news and insights for biopharma leaders
State of Play
Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over the past two decades.
|
Coartem Baby, which was cleared by health authorities in Switzerland, will fill an important gap in treatment. Novartis plans to sell it “largely” on a not-for-profit basis.
|
The cell therapy developer, which raised nearly $500 million in 2023 on the promise of its CAR-T work, has floundered since a safety setback forced it to scrap its lead candidate.
|
The complaint argues Kennedy’s actions to remove the COVID vaccine from the CDC's immunization schedule for pregnant people and healthy children were unlawful.
|
From the archives
Our story on targeted protein degraders is the latest in a series examining new areas of biotech investment, like sodium channel blockers and RNA editing.
|
Improve launch success and optimize investments
|
|
From Our Library
Playbook
Custom content for Premier Research
|
Playbook
Custom content for Medrio
|
Webinar - on demand
Custom content for PPD FSP solutions
|
Trendline
Supported by Quest Diagnostics
|
View all resources
What We’re Reading
The New York Times Magazine
| | 
